Abbott, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated are dominating the North America Non-Small Cell Lung Cancer Diagnostics Market in 2021

North America Non-Small Cell Lung Cancer Diagnostics Market is expected to grow with the CAGR of 13.0% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/north-america-non-small-cell-lung-cancer-diagnostics-market

North America non-small cell lung cancer diagnostics market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in North America non-small cell lung cancer diagnostics market are introducing strong range of products provider along with launching new certificates and adopting strategic initiative such as acquisition, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance:

• In June 2019, F. Hoffmann-La Roche Ltd launched an in-vitro diagnostic test, ROS1 immunohistochemistry assay, to diagnose VENTANA ROS1 (SP384) Antibody, indicating positive lung cancer. ROS 1 gene mutation is present in non-small cell lung cancer (NSCLC) cases. This new method is efficient as well as cost-effective. This new launch helped the company enhance their product portfolio and offer effective and efficient treatment for non-small cell lung cancer

Abbott is the dominating player in North America non-small cell lung cancer diagnostics market. The other key players existing in the market are F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., NanoString, Janssen Pharmaceutical NV, Inivata Ltd, bioMérieux SA, Biotheranostics, OncoCyte Corporation Inc., GENERAL ELECTRIC COMPANY, Eckert & Ziegler, DrLal PathLabs, RIVERAIN TECHNOLOGIES, PlexBio Co.,Ltd, Oncimmune, and Biodesix.

Abbott

Abbott was founded in the year 1903 and is headquartered in Illinois, U.S. The company is focused on delivering instruments and assay solutions to provide early diagnosis of diseases and for selection of appropriate therapies and to monitor diseases recurrence. The company has several product categories including featured products, instrumentation, infectious disease, informatics, oncology, genetics & genomics in which instrumentation, infectious disease, oncology is the market focused category.

For instance,

• In October 2012, Abbott  expanded its business by launching companion diagnostics, Vysis ALK Break Apart FISH Probe Kit in Europe, to diagnose non-small cell lung cancer patients eligible for XALKORI treatment

The company has wide presence across Asia-Pacific, Europe, America, South Africa and Middle East.

F. Hoffmann-La Roche Ltd

F. Hoffmann-La Roche Ltd was founded in the year 1896 and is headquartered in Basel, Switzerland. Their main focus of the company is on developing and integrating diagnostic solutions covering molecular diagnostics, clinical chemistry, immunoassays, tissue diagnostics, point of care testing, patient self-testing, next-generation sequencing, and laboratory automation and IT, and decision support solutions. The company operates its business via several business segments including pharmaceuticals, diagnostics in which diagnostics is the market focused segment.

For instance,

• In June, F. Hoffmann-La Roche Ltd launched automated digital pathology algorithm, uPath PD-L1 (SP263) image analysis  to diagnose non-small cell lung cancer (NSCLC) and improve the speed and accuracy of diagnosis treatment. This new launch of the algorithm helped the pathologiest to assess the disease more effectively

The company has presence across Europe, North America, Asia-Pacific, and Africa.

Quest Diagnostics Incorporated

Quest Diagnostics Incorporated was founded in the year 1967 and is headquartered in New Jersey, U.S. The main focus of the company is on providing diagnostics testing, information and services to patients, healthcare providers, pharmaceutical companies and life insurance companies. The company has product category in segments including solutions for physicians & hospitals, medical conditions, a focus on specialty in which medical conditions is the market focused category.

For instance,

• In June 2021, Quest Diagnostics Incorporated partnered with Biocept to offer its target selector next-generation sequencing (NGS)-based liquid biopsy targeted lung cancer panel to the customers and also use Biocept’s less invasive, lab-developed assay to conduct genomic profiling in advanced NSCLC patients. This partnership helped the company offer their product to a large consumer base and develop more advanced technology

The company has presence across Europe, North America, and Asia-Pacific.